Paradigm Biocapital Advisors’s Vor Biopharma VOR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.2M	Hold	1,750,000	–	–	0.6%	23
2026 Q1	$31.2M	Hold	1,750,000	–	–	0.64%	28
2025 Q4	$22.9M	Buy	+1,750,000	New	+$32.6M	0.58%	26
2024 Q3	–	Sell	-322,865	Closed	-$6.46M	–	41
2024 Q2	$6.46M	Hold	322,865	–	–	0.25%	33
2024 Q1	$15.3M	Hold	322,865	–	–	0.54%	29
2023 Q4	$14.5M	Sell	322,865 -208	-0.1%	-$8.58K	0.68%	26
2023 Q3	$13.7M	Hold	323,073	–	–	0.93%	25
2023 Q2	$20M	Sell	323,073 -827	-0.3%	-$75.5K	1.54%	25
2023 Q1	$34.9M	Buy	323,900 +1,759	+0.5%	+$195K	3.3%	17
2022 Q4	$42.8M	Buy	322,141 +236,959	+278%	+$23.4M	5.03%	10
2022 Q3	$6.78M	Buy	85,182 +19,967	+31%	+$1.96M	0.9%	27
2022 Q2	$6.48M	Buy	65,215 +20,495	+46%	+$2.1M	1.29%	19
2022 Q1	$5.4M	Buy	44,720 +13,253	+42%	+$2.26M	1.43%	21
2021 Q4	$7.31M	Buy	+31,467	New	+$9.07M	2.09%	19

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Paradigm Biocapital Advisors's VOR Position: Q2 2026 in Review

Paradigm Biocapital Advisors held its Vor Biopharma (VOR) position steady in Q2 2026 at 1,750,000 shares worth $32.2M. The position accounts for 0.6% of the portfolio, ranked #23.

Paradigm Biocapital Advisors first reported a position in VOR in Q4 2021 and has held it in 14 quarters since. The position peaked at $42.8M in Q4 2022. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Paradigm Biocapital Advisors held 1,750,000 shares of Vor Biopharma worth $32.2M as of Q2 2026.
Paradigm Biocapital Advisors left its Vor Biopharma share count unchanged in Q2 2026.
Vor Biopharma made up 0.6% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #23 holding.
Paradigm Biocapital Advisors first reported a position in Vor Biopharma in Q4 2021 and has held it in 14 quarters since.
Paradigm Biocapital Advisors's Vor Biopharma position peaked at $42.8M in Q4 2022.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.